MacroGenics Inc (MGNX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $138.68M
Last updated: Nov 17, 2026 at 4:15 PM ET
MacroGenics Inc (MGNX) Statistics
MacroGenics (MGNX) has a market cap of $138.68M and an enterprise value of $119.33M. It kept -45.36% of revenue as net income over the last 12 months. Revenue grew 22.82% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 13.96% below the market cap, as cash exceeds debt.
| Market Cap | $138.68M |
|---|---|
| Enterprise Value | $119.33M |
| Latest price (Nov 17, 2026) | $2.05 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 11, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.2x and 5.2x. Its year-end P/S ranged from 0.9x to 12.4x from 2016 to 2025.
| P/S Ratio | 1.2x |
|---|---|
| Forward P/S | 1.5x |
| P/B Ratio | 5.2x |
Price Statistics
The stock is up 36.67% over 52 weeks and trades 36.73% below its 50-day average.
| Beta (1Y) | 1.08 |
|---|---|
| 52-Week Change | +36.67% |
| 1-Month Change | -38.44% |
| 3-Month Change | -50.84% |
| 6-Month Change | -54.65% |
| 5-Year Change | -87.71% |
| 10-Year Change | -89.87% |
| Total Return (1Y) | +36.67% |
| Total Return (3Y CAGR) | -35.35% |
| Total Return (5Y CAGR) | -36.11% |
| Return vs SPY (1Y) | +21.56% |
| Max Drawdown (1Y) | -57.82% |
| Max Drawdown (3Y) | -95.06% |
| Sharpe Ratio (1Y) | 0.32 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $3.24 |
| 200-Day Average | $3.45 |
| 52-Week Range | $1.32 to $5.08 |
| RSI (14 Days) | 28.8 |
| Average Volume (20 Days) | 1.11M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.75x current liabilities, and total debt is 1.18x shareholder equity.
| Current Ratio | 2.75x |
|---|---|
| Quick Ratio | 2.75x |
| Debt / Equity | 1.18x |
| Interest Coverage | -4.27x |
Returns and Efficiency
Return on invested capital is -108.66% over the last 12 months, against a 5-year average of -69.37%.
| Return on Equity (ROE) | -204.72% |
|---|---|
| Return on Assets (ROA) | -16.16% |
| Return on Invested Capital (ROIC) | -108.66% |
| Return on Capital Employed (ROCE) | -35.66% |
| ROE (5Y Average) | -73.31% |
| ROA (5Y Average) | -32.13% |
| ROIC (5Y Average) | -69.37% |
| Asset Turnover | 0.39x |
| Receivables Turnover | 1.55x |
Scores
MGNX has an Altman Z-Score of -5.08, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -5.08 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $113.50M over the last 12 months.
| Revenue | $113.50M |
|---|---|
| Revenue Growth (YoY) | +22.82% |
| Gross Profit | $113.50M |
| Operating Income | -$79.69M |
| Pretax Income | -$142.70M |
| Net Income | -$51.49M |
| EBITDA | -$73.84M |
| EBIT | -$75.41M |
| Reported EPS (TTM) | -$1.41 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 7.89% of the $318.69M in total assets.
| Cash and Equivalents | $49.03M |
|---|---|
| Total Debt | $29.67M |
| Net Cash | $19.36M |
| Net Cash Per Share | $0.30 |
| Working Capital | $187.85M |
| Shareholder Equity | $25.15M |
| Book Value Per Share | $0.39 |
| Total Assets | $318.69M |
| Total Liabilities | $293.53M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.47M of capital spending, operating cash flow left -$41.34M of free cash flow.
| Operating Cash Flow | -$39.87M |
|---|---|
| Capital Expenditures | $1.47M |
| Free Cash Flow | -$41.34M |
| FCF Per Share | -$0.65 |
| Depreciation and Amortization | $7.03M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -70.21%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -70.21% |
| Pretax Margin | -125.72% |
| Net Margin | -45.36% |
| EBITDA Margin | -65.06% |
| EBIT Margin | -66.44% |
| FCF Margin | -36.42% |
| Gross Margin (5Y Average) | 98.55% |
| Net Margin (5Y Average) | -89.96% |
Growth
Revenue fell 0.54% a year over 3 years.
| Revenue Growth (3Y CAGR) | -0.54% |
|---|---|
| Revenue Growth (5Y CAGR) | +7.35% |
| Book Value Per Share Growth (2Y CAGR) | -40.23% |
| Tangible Book Per Share Growth (2Y CAGR) | -40.23% |
Dividends and Yields
MGNX does not pay a dividend. Its free cash flow yield is -31.63%.
| FCF Yield | -31.63% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 4 similar companies, MGNX has the lowest P/S.
P/S RatioPeer median 7.5x
ROICPeer median 4.62%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -99.11%
| P/S Ratio | 1.2x vs 7.5x median |
|---|---|
| ROIC | -108.66% vs 4.62% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +22.82% vs -99.11% median |
Analyst Forecast
Consensus estimates put revenue growth at -22.15% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -22.15% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MGNX
What is MGNX's market cap?
MacroGenics has a market cap of $138.68M. Its enterprise value, which adds debt and subtracts cash, is $119.33M.
How many shares of MGNX are outstanding?
MacroGenics has 63.74M shares outstanding. The count is up 0.81% from a year earlier.
Does MGNX pay a dividend?
No. MacroGenics does not pay a dividend.
How much debt does MGNX have?
MacroGenics has $29.67M of total debt and $49.03M of cash and equivalents, a net cash position of $19.36M.
MGNX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts